PHAT vs PLSE: fair value comparison
Phathom Pharmaceuticals, Inc. and Pulse Biosciences, Inc. · Updated 2026-10-19
PHAT's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. PLSE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PHAT currently ranks higher by quality score.
| PHAT | PLSE | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $6.92 | $44.43 |
| 12-month range | $6.70–$18.08 | $12.66–$55.20 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #206 of 301 Healthcare | #207 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Expanding |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: PHAT fair value analysis · PLSE fair value analysis